The results of QRT-PCR and western blot showed that CXCL5 treatment decreased the expression of epithelial marker E-cadherin while increased that of mesenchymal markers N-cadherin and Vimentin in GC cells. The gene discussed is CDH2; the disease is gastric cancer.